Home > Insider Trading > Filing (0001725160-22-000032)

Filing Details

Accession Number:: 0001725160-22-000032
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-02-14 21:09:19
Reporting Period:: 2022-02-10

Accepted Time:: 2022-02-14 21:09:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557832	Cam Gallagher	C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway, Suite 1710 New York NY 10018		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-02-10	8,203	$0.00	395,406	No	4	A	Direct
Common Stock	Acquisiton	2022-02-10	7,595	$0.00	403,001	No	4	A	Direct
Common Stock	Disposition	2022-02-14	2,079	$50.16	400,922	No	4	S	Direct
Common Stock	Disposition	2022-02-14	259	$50.75	400,663	No	4	S	Direct
Common Stock	Disposition	2022-02-14	4,850	$50.17	395,813	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-02-10	19,245	$0.00	19,245	$52.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
19,245		2032-02-09	No	4	A	Direct

Footnotes

Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in full on the first anniversary of the grant date.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.77 to $50.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.